This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John G. Gunderson, MD

Arch Gen Psychiatry. 1986;43(7):698-700.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In the early 1970s, when studies on borderline patients began in earnest, most inpatients received either an inadequate trial on any psychotropic drug or none at all. The literature of that period warned about the ineffectiveness^1,2 or actual harmfulness^3-7 of pharmacologic treatment for borderline patients.

A decade later, it had become rare for any inpatient with borderline personality disorder to be discharged without a vigorous trial of at least one psychotropic agent. Even in outpatient settings, the majority of patients had prior exposure to psychotropic medications.⁸ This proliferation of drug treatments for borderline patients had taken place despite the absence of any controlled evaluations. In fact, the additions to the literature largely consisted of case series from which claims were made for the usefulness of monoamine oxidase inhibitors,⁹ tricyclic antidepressants,¹⁰ and low-dose phenothiazines.¹¹ The greatly expanded awareness of the potential value of such pharmacotherapies . . . [Full Text PDF of this Article]

Author Affiliations
From the Psychosocial Research Program, McLean Hospital, Belmont, Mass.

Footnotes
Accepted for publication Jan 27, 1986.

Reprint requests to McLean Hospital, 115 Mill St, Belmont, MA 02178 (Dr Gunderson).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?